Pfizer asks FDA to OK fourth dose of COVID vaccine for seniors
CBSN
Pfizer and BioNTech have asked the Food and Drug Administration to greenlight a fourth dose of their COVID-19 vaccine for Americans 65 and older, the companies announced Tuesday, citing data from Israel suggesting that the additional booster could curb infections and severe illness in the highest-risk age group
"Right now, the way that we have seen, it is necessary, a fourth booster right now," Pfizer CEO Albert Bourla told "Face the Nation" in an interview that aired Sunday.
In a release on Tuesday, Pfizer and BioNTech pointed to an array of recently published studies as early evidence suggesting "that effectiveness against both symptomatic COVID-19 and severe disease caused by Omicron wanes 3 to 6 months after receipt of an initial booster."
